Asthma drug could stop cat allergy sneezes in their tracks

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active nonsmoking males and females between the ages of 18-65 with allergic rhinitis triggered by cat dander exposure. * Concomitant medication limited to "as needed" including for mild asthma. * Baseline resting blood pressure les than or equal to 140/90 mm Hg. * Baseline resting heart rate less than or equal to 100 beats/min. * Baseline NIFR must be ≥ 50 L/min. * Females of childbearing age may participate only if they have a negative urine pregnancy test, are non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study. * The ability to give informed consent and comply with study procedures. Exclusion Criteria: * Receiving immunotherapy for cat allergy * Predictable seasonal allergy during the study period * Newly (\< 2 weeks) diagnosed with Corona Virus Disease (COVID-19) * Regular use of controller medication for moderate to severe asthma * Subject works with cats or keeps a cat as a pet. * Inability or unwillingness to give written informed consent. * History of upper/lower respiratory tract infection, requiring systemic steroids, antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit. * History of adverse reaction or allergy to Zafirlukast * History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion. * History of cardiovascular diseases including uncontrolled hypertension (blood pressure \>160/100 mmHg), ischemic heart disease, congestive heart failure (New York Heart Association III or IV), valvular heart disease or cardiomyopathy (e.g., depressed left ventricular ejection fraction by echo, arrhythmias). * Known allergy or sensitivity to atropine or ipratropium bromide. * Documented or self-reported current history of alcoholism or drug abuse. * Baseline Spirometry Forced Expiratory Volume in first second (FEV1) \<70% of predicted * Participated in another research trial and received investigational drug within 30 days or 5 half-lives, whichever is longer * Unwillingness or inability to comply with study procedures.